Part 1/13:
The Vaccination Landscape in Singapore: Exploring the Choice of Sinovac Amidst the COVID-19 Pandemic
Singapore boasts a remarkable vaccination rate, with over 81% of its population having received at least their first dose of a COVID-19 vaccine. While most residents opted for well-known mRNA vaccines like Pfizer-BioNTech and Moderna, a notable number have chosen Chinese-made vaccines, particularly Sinovac, also known by its corporate name, Sinovac Biotech. This article delves into the factors influencing such choices, the efficacy and safety profiles of different vaccines, and what this means for public health in Singapore and beyond.